Allogene Therapeutics, Inc.

Listed Company

ALLOCIK 0001737287NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-190.89M

Total Assets

$415.90M

Equity

$292.54M

Shares Out

345.15M

Op. Cash Flow

$-149.25M

ALLO$1.81+45.56% · past yearDBEQ Basic

Daily closing prices

Business

Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell product candidates for cancer and autoimmune disease treatment. The company manufactures off-the-shelf T cells derived from healthy donors using proprietary gene-editing and manufacturing technologies. Lead programs include cemacabtagene ansegedleucel for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases, with clinical readouts anticipated in 2026.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue - related party	0	22,000	95,000	156,000	114
Research and development	150	192	243	256	220
General and administrative	57	65	72	79	74
Impairment of long-lived asset	2	16	13	0	0
Total operating expenses	209	273	328	336	294
Loss from operations	−209	−273	−328	−336	−180
Interest and other income, net	19	20	18	5	2
Interest expense	−1	−181,000	0	—	—
Other income (expense), net	215,000	−4	−18	−9	−4
Total other income (expense), net	18	16	472,000	−5	−2
Loss before income taxes	−191	−257	−327	—	−257
Income tax expense	0	−443,000	0	—	0
Net loss	−191	−258	−327	−340	−182
Net unrealized gain on available-for-sale investments	358,000	866,000	9	−7	−3
Net comprehensive loss	−191	−257	−318	−348	−185
Net loss per share, basic (in dollars per share)	−0.87	−1.32	−2.09	−2.38	−1.34
Net loss per share, diluted (in dollars per share)	−0.87	−1.32	−2.09	−2.38	−1.34
Weighted-average number of shares used in computing net loss per share, basic (in shares)	221	195	157	143	136
Weighted-average number of shares used in computing net loss per share, diluted (in shares)	221	195	157	143	136

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2023 2023-06-30
Cash and cash equivalents	52	75	83	69	155
Short-term investments	199	217	366	396	337
Prepaid expenses and other current assets	8	11	10	8	10
Total current assets	258	303	459	473	502
Long-term investments	8	81	0	32	53
Operating lease right-of-use asset	40	45	64	79	80
Property and equipment, net	73	86	99	103	106
Deposit placed in escrow	23	21	0	—	—
Restricted cash	10	10	10	10	10
Other long-term assets	4	2	7	10	9
Total assets	416	549	643	713	773
Accounts payable	4	5	6	6	10
Accrued and other current liabilities	28	30	31	31	44
Total current liabilities	33	36	37	37	55
Lease liability, noncurrent	75	83	88	90	92
Other long-term liabilities	16	8	5	5	5
Total liabilities	123	127	131	133	152
Commitments and Contingencies (Notes 6 and 7)	—	—	—	—	—
Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2025 and December 31, 2024; no shares were issued and outstanding as of December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.001 par value: 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 229,413,523 and 212,210,597 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	229,000	212,000	169,000	168,000	167,000
Additional paid-in capital	2,303	2,242	2,075	2,059	2,039
Accumulated deficit	−2,011	−1,820	−1,562	−1,476	−1,414
Accumulated other comprehensive gain (loss)	269,000	−89,000	−955,000	−2	−4
Total stockholders equity	293	422	512	581	621
Total liabilities and stockholders equity	416	549	643	713	773

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−191	−258	−327	−340	−182
Stock-based compensation	38	52	66	84	81
Depreciation and amortization	12	14	14	—	—
Net amortization/accretion on investment securities	−4	−8	−7	3	7
Impairment of equity investment and equity method investment	0	2	7	0	0
Non-cash rent expense	4	5	7	2	3
Non-cash collaboration revenue - related party	0	−14,000	−63,000	−104,000	−76
Share of loss from equity method investments	0	2	11	—	—
Deposit placed in escrow	−3	−21	0	—	—
Prepaid expenses and other current assets	3	−492,000	1	3	3
Other long-term assets	−1	4	−1	−3	−646,000
Accounts payable	−1	−503,000	−8	5	−767,000
Accrued and other current liabilities	−3	−1	−7	2	4
Operating lease liabilities	−8	−6	−6	—	—
Other long-term liabilities	1	259,000	−611,000	−2	910,000
Net cash used in operating activities	−149	−200	−238	−221	−185
Purchases of property and equipment	−386,000	−694,000	−2	−5	−21
Proceeds from sales of investments	0	5	6	0	0
Proceeds from maturities of investments	234	432	598	359	728
Purchase of investments	−138	−361	−439	−248	−526
Net cash provided by investing activities	96	76	163	106	164
Proceeds from issuance of common stock upon exercise of stock options	0	813,000	2	489,000	8
Proceeds from issuance of common stock under the employee stock purchase plan	895,000	2	2	2	4
Proceeds from CIRM award	7	2	0	—	—
Net cash provided by financing activities	30	117	96	3	12
Net decrease in cash, cash equivalents and restricted cash	−24	−8	21	−111	−9
Right-of-use asset obtained in exchange for lease liability	0	2	0	31	20
Property and equipment purchases in accounts payable and accrued and other current liabilities	107,000	64,000	0	678,000	2
Cash paid for amounts included in the measurement of lease liabilities	−13	−13	−12	−10	−6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Allogene Therapeutics, Inc.'s CIK number?

Allogene Therapeutics, Inc.'s SEC CIK number is 0001737287 (1737287). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Allogene Therapeutics, Inc.'s SEC filings?

All of Allogene Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Allogene Therapeutics, Inc. last report earnings?

Allogene Therapeutics, Inc. (ALLO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-034583). This is Allogene Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Allogene Therapeutics, Inc.'s most recent earnings 8-K?

Allogene Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001628280-26-034583. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Allogene Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →